ENDV - Endonovo Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0283
-0.0006 (-2.11%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.0289
Open0.0280
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.0261 - 0.0289
52 Week Range0.0150 - 0.0661
Volume2,574,872
Avg. Volume2,270,006
Market Cap12.294M
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.01800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Endonovo Therapeutics Issues Shareholder Letter and Update

    It is with great pleasure that I provide you with an update on Endonovo’s business development initiatives and our recent accomplishments. From a financing perspective, we recently entered into a line of credit at a 6% discount to market to reduce dilution for interim financing.

  • GlobeNewswire17 days ago

    Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today it has executed a Common Stock Purchase Agreement (the “Purchase Agreement”) with Azure Capital (“Azure”) to sell up to $10 Million in common stock to Azure over a term of 36 months, commencing after a registration statement related to the transaction has been filed and declared effective by the U.S. Securities and Exchange Commission. Alan Collier, CEO of Endonovo Therapeutics, stated, “We are excited about this partnership with Azure Capital and the opportunity of potential future access to capital at attractive terms.

  • GlobeNewswirelast month

    Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

    LOS ANGELES, CA, Dec. 18, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswirelast month

    Endonovo Expands SofPulse Commercialization

    LOS ANGELES, CA, Dec. 13, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire2 months ago

    Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company

    LOS ANGELES, CA, Dec. 03, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire2 months ago

    Endonovo Therapeutics Announces Complimentary New Product

    LOS ANGELES, CA, Nov. 08, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.